ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines
US FDA officials appears worried about workload created by product development and pre-submission meetings for complex generics.
You may also be interested in...
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.
Agency willing to talk to generic sponsors about complex product issues, but it can avoid the resource-intensive process by updating product-specific development guidances.
New CDER Direct NextGen Collaboration Portal allows sponsors of complex ANDAs to submit and track formal meeting requests.